Delcath Systems publishes review of Hepzato Kit

Delcath Systems (DCTH) announced the publication of a narrative review by leading interventional radiologists and oncologists from multiple institutions. The review, titled “Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion,” was published in the Journal of Vascular and Interventional Radiology and provides an overview of percutaneous hepatic perfusion with melphalan using Delcath’s Hepzato Kit. The narrative review synthesizes data from prospective and retrospective studies from centers in the U.S. and Europe, collectively demonstrating objective response rates of 36%-72%, median overall survival of 15-20 months, and disease control rates up to 89%. Key highlights include: PHP’s suitability for multifocal, bilobar UM liver metastases, delivering high-dose chemotherapy with extracorporeal filtration to minimize systemic toxicity. Short-stay hospital admissions with discharge within 24 hours. Advantages over other liver-directed therapies, such as reduced risk of hepatic fibrosis compared to radioembolization in whole-liver treatments. Quality of life data showing no long-term decline, with scores returning to baseline by Day 28 post-procedure. Ongoing research into immunotherapy combinations and expansion to other metastatic cancers like breast and colorectal